Coriolis Pharma Capabilities Update October 2026: Large Molecule

Turning Complex Molecules into Robust Drug Products

Developing biologics into stable, manufacturable drug products requires more than solving isolated formulation, analytical, or process challenges. Decisions made early in development can significantly impact stability, scalability, and long-term project success.

This presentation will illustrate how an integrated drug product development strategy helps biopharma companies identify developability risks earlier, generate actionable data, and make informed decisions throughout preclinical and clinical development. By combining predictive in silico simulations with experimental formulatability assessment, formulation and process development, non-GMP manufacturing, primary packaging selection, in-use studies, and advanced R&D and GMP analytics, complex development challenges can be addressed holistically rather than sequentially. Using examples from diverse biologic modalities, we will demonstrate how a science-driven, cross-functional approach accelerates development timelines, supports technology transfer readiness, and enables robust, stable, and manufacturable drug products.